Safely and well invested

Values & Performance of HAEMATO AG

Have you invested in HAEMATO AG or are you interested in the company's performance as a capital market participant? Here you will find all the important information about us and our activities: Current financial reports, key figures and our financial calendar.

Directly to the share price

€ 238 mio. sales in 2020

€ 1.00 per share dividend paid in 2021

635,000 packages sold annually

31 % sales CAGR since 2007

More than 7,000 customers

Investor News

With the current omicron wave, laboratories in Germany are facing a sharp increase in PCR testing. The evaluation capacities are pushing increasingly towards their limits, especially with regards to the new quarantine regulations.

Rating & Research

First Berlin Equity Research

Buy: 50,00 €

GBC AG

Buy: 50.10 €

Aktienkurs

Zum Aktienchart
HAEMATO annual report 2020 mockup

Safely and well advised

Reports

Get an overview of the status and development of HAEMATO AG. Here you will find information about the group as well as the developments of the past years.

Read reports

News

We would like to inform you about the current business development of HAEMATO AG as well as about our investor relations activities.

To the news archive

In operational terms, HAEMATO AG is heading for a record year following the acquisition of M1 Aesthetics GmbH. In addition, the expansion of their private label business is increasingly coming into focus. In this regard, the company plans to expand its portfolio with a botulinum toxin product under its own brand. GBC analyst Cosmin Filker spoke …

Investor News

HAEMATO continues to grow: consolidated revenue in the third quarter of 2021 increased by 9% year-over-year to EUR 65.1 million. From 1 January to 30 September 2021, consolidated revenue rose to 216.6 million euros. This corresponds to a growth of 23 % compared to the same period of the previous year. Group EBIT increased to 1.4 million euros in …

Ad-Hoc Mitteilung

Seoul and Schönefeld, 25th October 2021 - HAEMATO PHARM GmbH ("HAEMATO"), a wholly owned subsidiary of HAEMATO AG (ISIN: DE000289VV1) is expanding its own portfolio with a botulinum toxin product from the pharmaceutical company Huons BioPharma Co., Ltd. ("Huons BioPharma"), based in Seoul, Korea. For this purpose, Huons BioPharma and HAEMATO have …

Upcoming events

Preliminary Results

Preliminary Results 2021

Annual Report 2021

Preliminary Results

Q1 Results 2022

For investors

Do you have any further questions about the group? Our investor relations team is happy to help you..

Contact us